Bruce Steel Net Worth

Bruce Steel biography

Bruce D. Steel serves as President, Chief Executive Officer, Director of the Company. He served as our President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co-founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010, Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Prior to that, Mr. Steel was co-founder and Chief Executive Officer of Rincon Pharmaceuticals, Inc., a genetic engineering biotechnology company, from 2005 until its acquisition in 2008. Mr. Steel also previously served as the Head of Corporate Development at Ambit Biosciences Corporation from 2002 to 2005. Mr. Steel previously served on the board of directors of Zosano Pharma Corporation, a publicly-held biopharmaceutical company, from 2012 to 2017. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.

What is the salary of Bruce Steel?

As the President, Chief Executive Officer y Director of Equillium Inc, the total compensation of Bruce Steel at Equillium Inc is $1,358,870. There are 1 executives at Equillium Inc getting paid more, with Krishna Polu having the highest compensation of $1,508,120.

How old is Bruce Steel?

Bruce Steel is 53, he's been the President, Chief Executive Officer y Director of Equillium Inc since 2020. There are 5 older and 12 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.

What's Bruce Steel's mailing address?

Bruce's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 105, , LA JOLLA, CA, 92037.

Insiders trading at Equillium Inc

Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski y Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.

What does Equillium Inc do?

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

Equillium Inc executives and stock owners

Equillium Inc executives and other stock owners filed with the SEC include:

• Krishna Polu,
  Executive Vice President - Research and Development, Chief Medical Officer
• Bruce Steel,
  President, Chief Executive Officer, Director
• Daniel Bradbury,
  Executive Chairman of the Board
• Dr. Krishna R. Polu,
  Consultant
• Dr. Stephen Connelly Ph.D.,
  Chief Scientific Officer & Director
• Bruce D. Steel C.F.A.,
  Co-Founder, Pres, CEO & Director
• Stephen Connelly,
  Chief Scientific Officer, Director
• Daniel Mark Bradbury,
  Exec. Chairman
• Mark Pruzanski,
  Independent Director
• Charles McDermott,
  Independent Director
• Bala Manian,
  Independent Director
• Martha Demski,
  Independent Director
• Matthew Ritter,
  Vice President - Corporate Development
• Maple Fung,
  Vice President - Clinical Development
• Christine Zedelmayer,
  Chief Operating Officer, Senior Vice President
• Jason Keyes,
  Chief Financial Officer
• Jason A. Keyes,
  Chief Financial Officer
• Dr. Dolca Thomas M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Joel M. Rothman,
  Chief Devel. Officer
• Michael Moore,
  VP of Investor Relations & Corp. Communications
• Christine Zedelmayer M.B.A., P.M.P.,
  Sr. VP & COO
• Yu (Katherine) Xu,
  
• Sa Biocon,
  10% owner
• Dolca Thomas,
  Chief Medical Officer
• Joel Rothman,
  Chief Development Officer
• Barbara Troupin,